News & Updates

Treatment-naive patients with immediate-risk (IR) nonmuscle-invasive bladder cancer (NMIBC) who received gemcitabine appear to have greater recurrence risk than those given Bacillus Calmette-Guerin (BCG). Both treatments, however, are effective against disease progression.

Findings from the MITOS EROS+CP (US) study underscore the importance of prompt initiation of budesonide/glycopyrrolate/formoterol fumarate (BGF) following an exacerbation in patients with chronic obstructive pulmonary disease (COPD).

Older Southeast Asian adults showed a relatively poor understanding of telehealth services during the COVID-19 pandemic, and many of them held erroneous views regarding their use, according to a Singapore study.

A network meta-analysis (NMA) reports that the combination regimen comprising atezolizumab and bevacizumab appears to be better than other first-line systemic therapeutic alternatives for advanced hepatocellular carcinoma (HCC) in terms of providing a balance between overall survival (OS) benefit and quality of life (QoL) preservation.

The advent of new lipid-lowering agents, such as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, has led to guideline updates on management of chronic coronary syndrome (CCS) and acute coronary syndrome (ACS). In addition to potent LDL-cholesterol (LDL-C) reduction, alirocumab may mitigate atherosclerotic cardiovascular disease (ASCVD) risk by inducing plaque stabilization and exerting protective vascular effects.